NCT07016490View on ClinicalTrials.gov

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 30, 2027

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SSGJ-709

A bispecific antibody targeting PD-1 and LAG-3.

Trial Locations (1)

Unknown

RECRUITING

Southern Oncology Clinical Research Unit (SOCRU), Adelaide

All Listed Sponsors
collaborator

Macquarie University, Australia

OTHER

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY